BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
$ 10.84
arrow_upward
+0.23%(+0.025) 1D
10-р сарын 2, 16:00:00 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
$ 10.83
High
$ 10.85
Low
$ 10.74
Mkt. cap
2.61 тэрбум
Avg. vol.
3.68 мян
Volume
9.14 мян
P/E ratio
11.59
52-wk high
$ 13.00
52-wk low
$ 8.67
EPS
$ 0.93
Beta
1.45
Shares outstanding
237.82 сая
No. of employees
2 мян
Open
$ 10.83
High
$ 10.85
Low
$ 10.74
Mkt. cap
2.61 тэрбум
Avg. vol.
3.68 мян
Volume
9.14 мян
P/E ratio
11.59
52-wk high
$ 13.00
52-wk low
$ 8.67
EPS
$ 0.93
Beta
1.45
Shares outstanding
237.82 сая
No. of employees
2 мян
News stories
From web sources and news partners
01net
·
18 минутын өмнө
Surf Air Mobility Announces Employee Inducement Awards Under NYSE Rule 303A.08
Business Wire
·
17 минутын өмнө
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crowdfund Insider
·
1 цагийн өмнө
XRP Treasury Firm Evernorth Clears Shareholder Vote Ahead Of Oct 8 Nasdaq Debut
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
CEOPaul Chaplin
Employees1.91 мян
Founded1992 оны 7-р сарын 1
Headquarters-
Sector-
Websitebavarian-nordic.com